title: Impact of antiretroviral protocols on dynamics of AIDS progression markers.
abstract: OBJECTIVE
  To assess the "real life" effectiveness of different antiretroviral therapies (ART).
  
  
  METHODS
  A retrospective multicentre observational study in 150 HIV-1 vertically infected children on the progression to AIDS (study A), and in 61 HIV-1 infected children on the evolution of the most relevant markers of progression (study B). All children were categorised into four groups: untreated (NT); on monotherapy (MT); on combination therapy (dual-ART); and on potent ART (HAART).
  
  
  RESULTS
  No child in the HAART group progressed to AIDS, whereas 14 children in the NT and seven in the MT groups progressed to AIDS, respectively, the differences being statistically significant. There was a mean increase of 8 units of %CD4+ per year; this was greater in the HAART group than in the other groups. The mean decrease in viral load was 0.65 log(10) copies/ml per year; this was greater in the HAART group than in the NT and MT groups. The HAART group had the lowest probability of returning to baseline %CD4+ and viral load.
  
  
  CONCLUSIONS
  Potent ART had the greatest protective effect against progression to AIDS in this observational study.
authors.affiliation: Department of Immunology, General University Hospital "Gregorio Marañón", Madrid, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Resino
authors.forename: J M
authors.initials: JM
authors.lastname: Bellón
authors.forename: S
authors.initials: S
authors.lastname: Sánchez-Ramón
authors.forename: D
authors.initials: D
authors.lastname: Gurbindo
authors.forename: J
authors.initials: J
authors.lastname: Ruiz-Contreras
authors.forename: J A
authors.initials: JA
authors.lastname: León
authors.forename: J T
authors.initials: JT
authors.lastname: Ramos
authors.forename: M A
authors.initials: MA
authors.lastname: Muñóz-Fernández
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015415:Biomarkers; D018791:CD4 Lymphocyte Count; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D016014:Linear Models; D008137:Longitudinal Studies; D008297:Male; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers